AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
27. September 2024 08:33 ET
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...
AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
30. Januar 2023 08:00 ET
|
AmMax Bio, Inc.
Study designed to optimize treatment regimen and evaluate efficacy over six-month dosing period Initial results expected in second half of 2023 REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE)...
AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
19. Januar 2023 16:01 ET
|
AmMax Bio, Inc.
AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation Validates Unique Therapeutic Potential of AMB-05X as Demonstrated...
AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors
09. Januar 2023 08:00 ET
|
AmMax Bio, Inc.
This novel ADC is expected to have a wider therapeutic index and superior clinical profile across a broad range of solid tumors IND submission is planned for mid-2023 REDWOOD CITY, Calif. and...
AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at the 2022 CTOS Annual Meeting
18. November 2022 08:00 ET
|
AmMax Bio, Inc.
Using local administration for a local disease, positive clinical results suggest AMB-05X could become best-in-class treatment for the diverse population of TGCT patients Positive Proof-of-Concept...
AmMax Bio Provides Update on AMB-05X Program for Tenosynovial Giant Cell Tumor (TGCT)
26. September 2022 08:00 ET
|
AmMax Bio, Inc.
New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment for TGCT Positive Proof-of-Concept Results Lead to Extension of Phase 2 Study to...
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022
12. September 2022 08:00 ET
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including...
AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
07. September 2022 08:00 ET
|
AmMax Bio, Inc.
Proof-of-Concept Established in Phase 2 Trial of TGCT, with Positive Efficacy Results Across Multiple Clinical Endpoints and Favorable Safety Profile After 12 Weeks of Therapy with AMB-05X Novel,...
AmMax Bio Announces the Appointment of Dorothy Nguyen, M.D. as Vice President of Clinical Development
25. Juli 2022 08:00 ET
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including the...
AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Delivery of AMB-05X in Patients with Tenosynovial Giant Cell Tumor (TGCT)
02. März 2022 08:00 ET
|
AmMax Bio, Inc.
Intra-Articular Injection Strategy Shows Efficacy Across Multiple Clinical Endpoints and Favorable Safety Profile After 12 Weeks of Therapy Data From the Phase 2 Study Support the Potential of...